Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07404865 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
A Phase 3 study of Primary Sjogren's Disease, sponsored by Vor Biopharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 3
- Study locations
NCT07404865: Recruiting Phase 3 study of Primary Sjogren's Disease, sponsored by Vor Biopharma.
NCT07404865 is a Phase 3 study of Primary Sjogren's Disease that is actively recruiting participants, run by Vor Biopharma. The registered enrollment target is 250 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07404865, a Phase 3 study of Primary Sjogren's Disease, is actively recruiting participants, sponsored by Vor Biopharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
Primary Outcome
Change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Telitacicept
Study Locations (3)
Illinois
- Chicago Clinical Research Institute Inc - Chicago
Louisiana
- Accurate Clinical Research, Inc. - Lake Charles
Texas
- Accurate Clinical Research, Inc. - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2028-08 |
| Phase | Phase 3 |
What NCT07404865 shows while recruiting
NCT07404865 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Primary Sjogren's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07404865 reports a single indexed study location in Illinois, Louisiana, Texas.
Frequently Asked Questions
What is clinical trial NCT07404865 about?
NCT07404865 is a clinical study titled "Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease". Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
What is the current status of trial NCT07404865?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2026-02-26. Estimated completion is 2028-08.
What conditions does trial NCT07404865 study?
This clinical trial studies the following conditions: Primary Sjogren's Disease.
What interventions are being tested in trial NCT07404865?
The interventions under investigation include: Placebo (DRUG), Telitacicept (BIOLOGICAL).
Who is sponsoring clinical trial NCT07404865?
This trial is sponsored by Vor Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07404865 being conducted?
This trial has 3 study locations across Illinois, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sjogren's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07404865's enrollment target sits among peer trials
250 1250th of 2000 higher than 735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI